Cargando…

Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen

The safety and feasibility of oral fluoroquinolone monotherapy in patients with low-risk febrile neutropenia (FN) were demonstrated in recent studies. Levofloxacin (LVFX) is a commonly prescribed antibiotic; however, evidence for its efficacy against FN is limited. Therefore, in this study, we retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mogi, Ai, Sasaki, Hidenori, Nakashima, Yuta, Chinen, Shotaro, Ishizu, Masanao, Tanaka, Toshihiro, Takata, Tohru, Takamatsu, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596912/
https://www.ncbi.nlm.nih.gov/pubmed/32779614
http://dx.doi.org/10.3960/jslrt.20008
_version_ 1783602213392744448
author Mogi, Ai
Sasaki, Hidenori
Nakashima, Yuta
Chinen, Shotaro
Ishizu, Masanao
Tanaka, Toshihiro
Takata, Tohru
Takamatsu, Yasushi
author_facet Mogi, Ai
Sasaki, Hidenori
Nakashima, Yuta
Chinen, Shotaro
Ishizu, Masanao
Tanaka, Toshihiro
Takata, Tohru
Takamatsu, Yasushi
author_sort Mogi, Ai
collection PubMed
description The safety and feasibility of oral fluoroquinolone monotherapy in patients with low-risk febrile neutropenia (FN) were demonstrated in recent studies. Levofloxacin (LVFX) is a commonly prescribed antibiotic; however, evidence for its efficacy against FN is limited. Therefore, in this study, we retrospectively investigated the efficacy of LVFX against low-risk FN in patients with malignant lymphoma at our institution. Treatment success was defined as recovery from fever and neutropenia without alteration of the initial regimen. We recruited 29 patients between January 2013 and December 2018. The median age of the cohort was 64 (range: 21–87) years; 13 (44.8%) were aged over 65 years. In total, 22 patients had diffuse large B-cell lymphoma (DLBCL). Therapy was successful in 24 (82.8%) patients, whereas 5 had treatment failure requiring a change from LVFX to intravenous broad-spectrum antibacterial agents. No deaths related to FN were observed. Two patients required FN-related chemotherapy dose reduction in subsequent cycles. Although this cohort comprised many elderly patients, our study confirmed the efficacy of LVFX in patients with low-risk FN. This may improve the treatment of low-risk FN and malignant lymphoma.
format Online
Article
Text
id pubmed-7596912
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher JSLRT
record_format MEDLINE/PubMed
spelling pubmed-75969122020-11-03 Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen Mogi, Ai Sasaki, Hidenori Nakashima, Yuta Chinen, Shotaro Ishizu, Masanao Tanaka, Toshihiro Takata, Tohru Takamatsu, Yasushi J Clin Exp Hematop Original Article The safety and feasibility of oral fluoroquinolone monotherapy in patients with low-risk febrile neutropenia (FN) were demonstrated in recent studies. Levofloxacin (LVFX) is a commonly prescribed antibiotic; however, evidence for its efficacy against FN is limited. Therefore, in this study, we retrospectively investigated the efficacy of LVFX against low-risk FN in patients with malignant lymphoma at our institution. Treatment success was defined as recovery from fever and neutropenia without alteration of the initial regimen. We recruited 29 patients between January 2013 and December 2018. The median age of the cohort was 64 (range: 21–87) years; 13 (44.8%) were aged over 65 years. In total, 22 patients had diffuse large B-cell lymphoma (DLBCL). Therapy was successful in 24 (82.8%) patients, whereas 5 had treatment failure requiring a change from LVFX to intravenous broad-spectrum antibacterial agents. No deaths related to FN were observed. Two patients required FN-related chemotherapy dose reduction in subsequent cycles. Although this cohort comprised many elderly patients, our study confirmed the efficacy of LVFX in patients with low-risk FN. This may improve the treatment of low-risk FN and malignant lymphoma. JSLRT 2020-08-08 /pmc/articles/PMC7596912/ /pubmed/32779614 http://dx.doi.org/10.3960/jslrt.20008 Text en © 2020 by The Japanese Society for Lymphoreticular Tissue Research https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License.
spellingShingle Original Article
Mogi, Ai
Sasaki, Hidenori
Nakashima, Yuta
Chinen, Shotaro
Ishizu, Masanao
Tanaka, Toshihiro
Takata, Tohru
Takamatsu, Yasushi
Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen
title Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen
title_full Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen
title_fullStr Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen
title_full_unstemmed Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen
title_short Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen
title_sort efficacy of oral levofloxacin monotherapy against low-risk fn in patients with malignant lymphoma who received chemotherapy using the chop regimen
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596912/
https://www.ncbi.nlm.nih.gov/pubmed/32779614
http://dx.doi.org/10.3960/jslrt.20008
work_keys_str_mv AT mogiai efficacyoforallevofloxacinmonotherapyagainstlowriskfninpatientswithmalignantlymphomawhoreceivedchemotherapyusingthechopregimen
AT sasakihidenori efficacyoforallevofloxacinmonotherapyagainstlowriskfninpatientswithmalignantlymphomawhoreceivedchemotherapyusingthechopregimen
AT nakashimayuta efficacyoforallevofloxacinmonotherapyagainstlowriskfninpatientswithmalignantlymphomawhoreceivedchemotherapyusingthechopregimen
AT chinenshotaro efficacyoforallevofloxacinmonotherapyagainstlowriskfninpatientswithmalignantlymphomawhoreceivedchemotherapyusingthechopregimen
AT ishizumasanao efficacyoforallevofloxacinmonotherapyagainstlowriskfninpatientswithmalignantlymphomawhoreceivedchemotherapyusingthechopregimen
AT tanakatoshihiro efficacyoforallevofloxacinmonotherapyagainstlowriskfninpatientswithmalignantlymphomawhoreceivedchemotherapyusingthechopregimen
AT takatatohru efficacyoforallevofloxacinmonotherapyagainstlowriskfninpatientswithmalignantlymphomawhoreceivedchemotherapyusingthechopregimen
AT takamatsuyasushi efficacyoforallevofloxacinmonotherapyagainstlowriskfninpatientswithmalignantlymphomawhoreceivedchemotherapyusingthechopregimen